



(Please scan this QR code to view the Red Herring Prospectus)

# CHANDAN HEALTHCARE LIMITED

Our Company was incorporated as a public limited Company under the name “Chandan Healthcare Limited”, under the provisions of the Companies Act, 1956 and Certificate of Incorporation was issued by the Registrar of Companies, U.P. & Uttaranchal, Kanpur on September 03, 2003. For details of incorporation, change of name and registered office of our Company, please refer to chapter titled “**General Information**” and “History and Certain Corporate Matters” beginning on page 75 and 191 respectively of the Red Herring Prospectus.

**Registered office and Corporate Office:** Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow- 226021, Uttar Pradesh, India; **Tel:** +91 8429024430; **E-mail:** secretarial@chandan.co.in; **Website:** www.chandandidiagnostic.com  
**Contact Person:** Rajeev Nain, Company Secretary & Compliance Officer; **Corporate Identity Number:** U85110UP2003PLC193493

**OUR PROMOTERS: AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED, AMAR SINGH, ASMITA SINGH, ALOK SINGH, SHALEEN SOLANKI, VIJAY SINGH AND VINAY LAMBA**

**THE OFFER IS BEING MADE INACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (EMERGE PLATFORM OF NSE OR NSE)**

## THE OFFER

INITIAL PUBLIC OFFERING OF UP TO 67,52,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH (“EQUITY SHARES”) OF CHANDAN HEALTHCARE LIMITED (“COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹ [•] LAKHS COMPRISING A FRESH ISSUE OF UP TO 44,52,064 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS BY OUR COMPANY (“FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 22,99,936 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS (THE “OFFERED SHARES”) COMPRISING OF UP TO 17,54,936 EQUITY SHARES BY AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED, UP TO 1,10,000 EQUITY SHARES BY JAGJEET SINGH KALSI, UP TO 1,00,000 EQUITY SHARES BY DEEPAK KUMAR SIROHI, UP TO 50,000 EQUITY SHARES BY AJAI SINGH, UP TO 50,000 EQUITY SHARES BY BIMLA SINGH, UP TO 50,000 EQUITY SHARES BY VIKAS LAMBA, UP TO 50,000 EQUITY SHARES BY ANCHAL SIROHI, UP TO 50,000 EQUITY SHARES BY HARI SHANKER DIXIT, UP TO 50,000 EQUITY SHARES BY SHITAL SINGH SOLANKI, UP TO 25,000 EQUITY SHARES BY VIKALP DIXIT AND UP TO 10,000 EQUITY SHARES BY BRAHM PRAKASH AGGREGATING UP TO ₹ [•] LAKHS (THE “SELLING SHAREHOLDERS” AND SUCH OFFER, THE “OFFER FOR SALE”) (THE “OFFER FOR SALE” AND TOGETHER WITH THE FRESH ISSUE, THE “OFFER”) OF WHICH 3,39,200 EQUITY SHARES AGGREGATING TO ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE OFFER (THE “MARKET MAKER RESERVATION PORTION”). THE OFFER INCLUDES A RESERVATION OF UP TO 2,45,600 EQUITY SHARES, AGGREGATING UP TO ₹ [•] LAKHS, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (AS DEFINED HEREIN) NOT EXCEEDING [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL (“EMPLOYEE RESERVATION PORTION”). THE OFFER, LESS EMPLOYEE RESERVATION AND MARKET MAKER RESERVATION, I.E. NET OFFER [•] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT PRICE OF ₹ [•] PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET OFFER”. OUR COMPANY AND THE SELLING SHAREHOLDERS MAY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER, OFFER A DISCOUNT UP TO ₹ [•] OF THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION (“EMPLOYEE DISCOUNT”). THE OFFER AND THE NET OFFER WILL CONSTITUTE 27.61% AND 25.22% RESPECTIVELY OF THE FULLY-DILUTED POST- OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES.

## DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE PRICE PER EQUITY SHARE

Name of Selling Shareholders	Type	Maximum number of Offered Shares	Weighted average cost of acquisition per Equity Share (In ₹)*
Amaranita Holdings (India) Private Limited	Promoter Selling Shareholder	Up to 17,54,936	10
Jagjeet Singh Kalsi	Investor Selling Shareholder	Up to 1,10,000	10
Deepak Kumar Sirohi	Investor Selling Shareholder	Up to 1,00,000	10
Ajai Singh	Promoter group Selling Shareholder	Up to 50,000	10
Bimla Singh	Promoter group Selling Shareholder	Up to 50,000	3.43
Vikas Lamba	Promoter group Selling Shareholder	Up to 50,000	10
Shital Singh Solanki	Promoter group Selling Shareholder	Up to 50,000	10
Anchal Sirohi	Investor Selling Shareholder	Up to 50,000	10
Hari Shanker Dixit	Investor Selling Shareholder	Up to 50,000	10
Vikalp Dixit	Investor Selling Shareholder	Up to 25,000	10
Brahm Prakash	Investor Selling Shareholder	Up to 10,000	10

\*As certified by M/s MSNT & Associates LLP, Chartered Accountants, Statutory and Peer Review Auditor by way of their certificate dated February 01, 2025

**Our Company: We run a diagnostic network in North India with pathology and radiology testing services. Our test menu includes (a) 481 routine pathology tests, covering basic biochemistry and hematology, as well as 1,015 specialized pathology tests, such as immohistopathology, and molecular pathology, and (b) 545 radiology tests, including basic x-rays, ultrasonography (“USG”), computed tomography (“CT”), magnetic resonance imaging (“MRI”), and specialized CT scans**

The Offer is being made in accordance with regulation 229(2) of the SEBI ICDR regulations

**QIB CATEGORY: NOT MORE THAN 50% OF THE NET OFFER**

**NON-INSTITUTIONAL INVESTOR CATEGORY: NOT LESS THAN 15% OF THE NET OFFER**

**RETAIL CATEGORY: NOT LESS THAN 35% OF THE NET OFFER MARKET MAKER PORTION: UPTO 3,39,200 EQUITY SHARES OR 5.02% OF THE OFFER.**

**EMPLOYEE RESERVATION PORTION: UP TO 2,45,600 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS**

**PRICE BAND: ₹ 151 TO ₹ 159 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH.**

**THE FLOOR PRICE 15.10 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 15.90 TIMES OF THE FACE VALUE.**

**BIDS CAN BE MADE FOR A MINIMUM OF 800 EQUITY SHARES AND IN MULTIPLES OF 800 EQUITY SHARES THEREAFTER.**

## RISKS TO INVESTORS:

i.The average cost of acquisition per Equity Share by our Promoters is set forth in the table below:

Name of the Promoters	No. of shares held	Average Cost of Acquisition (in ₹)
Amaranita Holdings (India) Private Limited	58,43,000	10
Amar Singh	23,19,860	10.52
Asmita Singh	1,62,000	10
Alok Singh	3,00,000	2.38
Shaleen Solanki	9,00,000	10
Vijay Singh	8,99,400	10
Vinay Lamba	15,84,800	10

and the Offer price at the upper end of the price band is ₹ 159 per Equity Share.

ii.Weighted Average Cost of Acquisition for all Equity Shares transacted in one year, eighteen months and three years preceding the date of the Red Herring Prospectus by all the shareholders:

Period	Weighted Average Cost of Acquisition (in ₹) <sup>#</sup>	Upper end of the Price band (₹ 159 is ‘X’ times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price (in ₹)
Last 1 year	10.28	15.47	₹ 0 - ₹ 16
Last 18 months	10.28	15.47	₹ 0 - ₹ 16
Last 3 years	6.72	23.66	₹ 0 - ₹ 16

<sup>#</sup>As certified by our Statutory and Peer Review Auditor, by way of their certificate dated February 04, 2025.

iii.The Price/Earnings ratio based on diluted EPS for Fiscal 2024 for our Company at the upper end of the Price Band is 19.53 times.

iv.Weighted Average Return on Net Worth for fiscals 2024, 2023 and 2022 is 23.10%

v.The Weighted average cost of acquisition compared to floor price and cap price.

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price ₹ 151	Cap Price ₹ 159
WACA of Primary Offer (except for bonus Offer)	NA	NA	NA
WACA for Secondary sale/ acquisitions not exceeding 5% of the pre-Offer capital	NA	NA	NA
WACA average cost of acquisition of past primary issuances / secondary in last 3 years.	6.72	22.47	23.66

vi. Any interruptions at our flagship diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.

vii. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.

viii.The BRLM associated with the Offer have handled 21 public issues in the past three years, out of which one issue closed below the issue price on listing date.

Investors should read the RHP carefully, including the “Risk Factors” on page 42 of the RHP before making any investment decision.

## BID/OFFER PROGRAMME

**ANCHOR INVESTOR BID/ OFFER PERIOD: FRIDAY, FEBRUARY 07, 2025\***

**BID/OFFER OPENS ON: MONDAY, FEBRUARY 10, 2025**

**BID/OFFER CLOSES ON: WEDNESDAY, FEBRURAY 12, 2025\*\***

\* Our Company in consultation with the BRLM, may consider participation by Anchor Investors, in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Offer Opening Date.

\*\*Our Company in consultation with the BRLM, may decide to close the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date, in accordance with the SEBI ICDR Regulations.


\*\*\*UPI Mandate end time and date shall be at 5:00 pm, on bid/offer closing date.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid /Offer Period for a minimum of one Working Day, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the respective websites of the BRLM and at the terminals of the members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.



This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“**SCRR**”) read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“**QIBs**”) (the “**QIB Portion**”), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis (“**Anchor Investor Portion**”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (“**Net QIB Portion**”). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“**SCSBs**”) or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see “Offer Procedure” on page 386.

**Bidders / Applicants should ensure that DP ID, PAN and Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidder/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to an Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants’ sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, and press release dated June 25, 2021.**

<div>ASBA*</div>	<div>Simple, safe, smart way of Application!!!!</div>	<div>*Applications supported by blocked amount (ASBA) is a better way of applying to offers by simply blocking the fund in the bank account. For further details, check section on ASBA below.</div> <div>Mandatory in Public offers. No cheque will be accepted.</div>
<div><div>UPI UNITED PAYMENTS INTERFACE</div></div>	<div>UPI- Now available in ASBA for all individual investors applying in public Offers where the application amount is up to 5,00,000, applying through Registered Brokers, Syndicate, CDPs &amp; RTAs. UPI-Now mandatory in ASBA for Retail Individual Bidders (“RIBs”) applying through Registered Brokers, DPs &amp; RTA. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.</div> <div>Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021.</div> <div>*ASBA has to be availed by all the investors. UPI may be availed by Retail Individual Bidders.</div> <div>For details on the ASBA and UPI process, please refer to the details given in ASBA Form &amp; abridged prospectus and also please refer to the section “Offer Procedure” beginning on page 386 of the RHP. The process is also available on the website of AIBI and Stock Exchange in the General information Document. ASBA Forms can be downloaded from the NSE Limited (“NSE”) and can be obtained from the list of banks that is displaying on website of SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>. List of banks supporting UPI is also available on the website of SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>. For the list of UPI Apps and Banks live on IPO, please refer to the link: <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>. Kotak Mahindra Bank Limited has been appointed as Sponsor Bank for the Offer in accordance with the requirements of the SEBI Circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail Id: <a href="mailto:ipo.upi@npci.org.in">ipo.upi@npci.org.in</a></div>	

**CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AS REGARDS ITS OBJECTS:** For information on the main objects and other objects of our Company, see “History and Certain Corporate Matters” on page 191 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see the section “Material Contracts and Documents for Inspection” on page 447 of the RHP.

**LIABILITY OF MEMBERS OF THE COMPANY:** Limited by shares.

**AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE:** The authorized share capital of the Company is ₹ 25,00,00,000 divided into 2,50,00,000 Equity Shares of ₹ 10 each. The Offered, subscribed, and paid-up share capital of the Company before the Offer is ₹ 20,00,00,000 divided into 2,00,00,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see chapter titled “Capital Structure” beginning on page 87 of the RHP.

**NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:** Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed by them at the time of signing of the Memorandum of Association of our Company: Amar Singh (10,000 Equity Shares); Virendra Singh (10,000 Equity Share); Vishal Lamba (10,000 Equity Shares); Vikas Lamba (5,000 Equity Shares); Ajay Singh (5,000 Equity Shares); Asmita Singh (5,000 Equity Shares); Anita Singh (2,000 Equity Shares); Vinay Lamba (1,000 Equity Shares); Shaleen Solanki (1,000 Equity Shares) and Mahabir Prasad Jain (1,000 Equity Shares) of ₹ 10 each.

**LISTING:** The Equity Shares Offered through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of NSE Limited (“**NSE EMERGE**”) in terms of the Chapter IX of the SEBI (ICDR) Regulations, as amended from time to time. Our Company has received an approval letter dated January 14, 2025, from NSE for using its name in the Offer Document for listing of our shares on the Emerge Platform of NSE. For the purpose of this Offer, the Designated Stock Exchange will be the NSE.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”):** Since the Offer is being made in terms of chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not Offer any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 361 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF NSE (“NSE EMERGE”) (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE should not in any way be deemed of construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 363 of the RHP for the full text of the Disclaimer Clause of NSE.

**TRACK RECORD OF BOOK RUNNING LEAD MANAGER:** The Merchant Banker associated with the Offer has handled 10 main board public issues and 11 SME public issues in the past three financial years.

**GENERAL RISK:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares Offered in the Offer have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section titled “Risk Factors” beginning on page 42 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE OFFER	COMPANY SECRETARY & COMPLIANCE OFFICER
<div><div>UNISTONE</div></div> <div><b>UNISTONE CAPITAL PRIVATE LIMITED</b> A/305, Dynasty Business Park Andheri-Kurla Road, Andheri East, Mumbai – 400 059. <b>Telephone:</b> 022 4604 6494 <b>Email:</b> <a href="mailto:mb@unistonecapital.com">mb@unistonecapital.com</a> <b>Investor grievance email:</b> <a href="mailto:compliance@unistonecapital.com">compliance@unistonecapital.com</a> <b>Contact Person:</b> Brijesh Parekh <b>Website:</b> <a href="http://www.unistonecapital.com">www.unistonecapital.com</a> <b>SEBI registration number:</b> INM000012449 <b>CIN:</b> U65999MH2019PTC330850</div>	<div><div>KFINTECH EXPERIENCE TRANSFORMATION</div></div> <div><b>KFin Technologies Limited</b> Selenium Tower-B, Plot 31 &amp; 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana <b>Telephone:</b> +91 40 6716 2222 <b>Email:</b> <a href="mailto:chl.ipo@kfintech.com">chl.ipo@kfintech.com</a> <b>Investor grievance email:</b> <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a> <b>Contact Person:</b> M Murali Krishna <b>Website:</b> <a href="http://www.kfintech.com">www.kfintech.com</a> <b>SEBI Registration Number:</b> INR000000221</div>	<div><b>Rajeev Nain,</b> <b>Chandan Healthcare Limited</b> Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow- 226021, Uttar Pradesh, India <b>Telephone:</b> +91 8429024430 <b>Website:</b> <a href="http://www.chandandidiagnostic.com">www.chandandidiagnostic.com</a> <b>Email id:</b> <a href="mailto:secretarial@chandan.co.in">secretarial@chandan.co.in</a></div> <div>Investors can contact the Company Secretary and Compliance Officer, BRLM or the Registrar to the Offer in case of any pre- Offer or post Offer related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode.</div>

**AVAILABILITY OF RHP:** Investors should note that investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Red Herring Prospectus and the Risk Factor contained therein, before applying in the Offer. Full copy of the Red Herring Prospectus shall be available at the website of Stock Exchange [www.nseindia.com](http://www.nseindia.com), the website of Book Running Lead Manager [www.unistonecapital.com](http://www.unistonecapital.com) and from the Registered Office of the Company.

**AVAILABILITY OF BID-CUM-APPLICATION FORMS:** Bid-Cum-Application forms can be obtained from the Registered Office of the **Company: Chandan Healthcare Limited** (Telephone: +91 8429024430) **BRLM: Unistone Capital Private Limited** (Telephone: 022-4604 6494) **Syndicate Member: R.K. Stockholding Private Limited** (Telephone: 011-48564444), Registered Brokers, RTA and CDPs participating in the Offer. Bid-cum-application Forms will also be available on the websites of, NSE ([www.nseindia.com](http://www.nseindia.com)) and the designated branches of SCSBs, the list of which is available at websites of the Stock Exchange and SEBI.

**SYNDICATE MEMBER:** R.K. Stockholding Private Limited

**BANKERS TO THE OFFER/ SPONSOR BANK / ESCROW COLLECTION BANK / PUBLIC OFFER BANK / REFUND BANK:** ICICI Bank Limited

**UPI:** UPI Bidders can also Bid through UPI Mechanism

**All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.**

**For CHANDAN HEALTHCARE LIMITED**  
On Behalf of the Board of Directors  
**Sd/-**  
**Amar Singh**  
**Chairman & Managing Director**

**Place:** Lucknow  
**Date:** February 04, 2025.

**CHANDAN HEALTHCARE LIMITED** is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the RHP with Registrar of Companies on February 04, 2025. The RHP shall be available on the website of the BRLM to the Offer at [www.unistonecapital.com](http://www.unistonecapital.com) and websites of NSE i.e. [www.nseindia.com](http://www.nseindia.com). Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled “Risk Factors” beginning on page 42 of the RHP. Potential investors should not rely on the DRHP for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.